Follicular Lymphoma
Conditions
Brief summary
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Detailed description
Primary Objectives: The primary objective of this study is to determine the safety of standard of care axicabtagene ciloleucel with bridging radiotherapy (RT) in patients with relapsed or refractory follicular lymphoma, as assessed by the incidence of grade 3 or higher cytokine release syndrome (CRS) within 30 days after chimeric antigen receptor (CAR) T-cell infusion. Secondary Objectives: * Establish the rates of CRS and ICANS in patients treated with CAR T-cell therapy and radiation * Determine complete response rate (CR) at approximately 1 month post CAR T-cell ---therapy * Determine complete response rate (CR) at approximately 6 month post CAR T-cell ---therapy * Determine the overall response rate (ORR) * Determine the duration of response (DOR) * Determine progression free survival (PFS) * Determine overall survival (OS) Exploratory Objectives: * Assess the impact of tumor burden as measured by metabolic tumor volume and total lesion glycolysis on PET/CT on response following CAR T-cell infusion * Assess T-cell fitness from blood samples by flow cytometry and ssRNAseq prior to and after bridging RT * Perform immune profiling of blood samples for T-cell subsets prior to and after bridging RT * Assess cytokine profile after infusion
Interventions
DRUGAxicabtagene Ciloleucel
Given by IV (vein)
DRUGCyclophosphamide
Given by IV (vein)
DRUGFludarabine phosphate
Given by IV (vein)
DRUGPrednisone
Given by IV (vein)
DRUGDiphenhydramine
Given by IV (vein)
DRUGAcetaminophen
Given by IV (vein)
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Eligible subjects will be considered for inclusion if they meet all of the following criteria: * Men and women 18 years of age or older * Histologically proven FL (Grade 1-3A) on most recent biopsy, history of transformed follicular lymphoma permitted at clinician discretion) * Patients with follicular lymphoma must have disease that has relapsed or is refractory to 2 or more prior lines of systemic therapy * (ECOG) performance status of 0-2 * Medically appropriate for CAR-T cell therapy: adequate organ function CrCL \>/= 45 mL/min/m2, hemoglobin level ≥ 8 g/dl, serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 x ULN if documented liver involvement, baseline oxygen saturation levels (SpO2) ≥92% on room air * Have at least 1 measurable lesion on imaging, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) and ≥1 cm on CT, MRI, or clinical exam. * Prior radiation therapy is permitted provided normal tissue tolerance is not exceeded * Female of child-bearing potential (FOCBP, defined below) must have a negative pregnancy test within 1 week of simulation for RT * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* History of other (non B-cell lymphoma) invasive malignancy requiring active therapy (systemic therapy, radiation, or surgery) within the past 3 years, excluding non-melanomatous skin cancer * Women of childbearing potential who are pregnant * Women who are breastfeeding and unwilling to discontinue prior to lymphodepleting chemotherapy and for 12 months following lymphodepleting chemotherapy and CAR-T cell infusion * Urgent need for bridging chemotherapy or rituximab between apheresis and CAR T cell product infusion (steroids permitted) * Additional RT would exceed standard organ at risk constraints * History of severe, immediate hypersensitivity reaction attributed to aminoglycosides * Uncontrolled fungal, bacterial, or viral infection requiring intravenous antimicrobials for management. Urinary tract infection and uncomplicated bacterial pharyngitis is permitted if responding to active treatment. Recent COVID19 infection is permitted if patient is deemed medically stable for CAR-T cell therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 | through study completion; an average of 1 year |
Countries
United States
Contacts
CONTACTSusan Wu, MD
PRINCIPAL_INVESTIGATORSusan Wu, MD
M.D. Anderson Cancer Center
Outcome results
None listed